{"nctId":"NCT00291655","briefTitle":"Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).","startDateStruct":{"date":"2006-06"},"conditions":["Epilepsy"],"count":130,"armGroups":[{"label":"Levetiracetam (LEV)","type":"EXPERIMENTAL","interventionNames":["Drug: Levetiracetam"]}],"interventions":[{"name":"Levetiracetam","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male/female adult subjects (â‰¥ 16 or 18 years)\n* Diagnosis of epilepsy (all types of seizures may be included)\n* Subjects who completed N01175 (NCT00175903) trial and benefited from levetiracetam monotherapy\n\nOther inclusion criteria may apply\n\nExclusion Criteria:\n\n* Subjects withdrawn from N01175 (NCT00175903) trial for any reason\n* Subjects who received treatment other than levetiracetam in N01175 (NCT00175903) trial\n* Subject requiring add-on antiepileptic treatment\n* Subjects from countries where levetiracetam is authorized for use as monotherapy in epilepsy treatment\n* Sexually active woman with childbearing potential who is not using a medically accepted birth control method","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase","description":"Summarization for occurrence of adverse events like number of subjects with any adverse events or drug related adverse events is provided (see categories).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight to Withdrawal or End of Study After 18 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"3.16"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":130},"commonTop":["Weight increased","Weight decreased"]}}}